Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Inclusion Criteria:

- Documented diagnosis of adult-onset axial SpondyloArthritis (axSpA) with at least 3
months' symptom duration and meet the Assessment of SpondyloArthritis International
Society (ASAS) criteria for axSpA and symptom duration of less than 5 years prior to
the participation of this study

- Active disease at Screening as defined by

- Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥ 2.1

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4

- Spinal pain > 4 on a 0 to 10 Numerical Rating Scale (NRS) (from BASDAI Item 2)

- for modified New York (mNY) -negative subjects only: C-reactive Protein (CRP) >
upper limit of normal (ULN) and/or current evidence for sacroiliitis on the
Screening Magnetic Resonance Imaging (MRI)

- Inadequate response to, or contraindication to, or intolerant to at least 2
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Exclusion Criteria:

- Presence of total Spinal Ankylosis ('bamboo spine')

- Diagnosis of any other Inflammatory Arthritis

- Prior treatment with any experimental biological agents for treatment of Axial
SpondyloArthritis (SpA)

- Exposure to more than 1 TNF-antagonist or primary failure to TNF antagonist therapy

- History of or current chronic or recurrent infections

- High risk of infection

- Recent live vaccination

- Concurrent malignancy or a history of malignancy

- Class III or IV congestive heart failure - New York Heart Association (NYHA)

- Demyelinating disease of the central nervous system

- Female subjects who are breastfeeding, pregnant or plan to become pregnant during the
study or within 3 months following the last dose of the investigational product

- Subjects with any other condition which, in the investigator's judgment, would make
the subject unsuitable for inclusion in the study